Stacy Dixon, MD, PhD

Assistant Professor, Neurology


FacultyPhoto
Medical School
  • MD, Indiana University School of Medicine (2012)
Graduate School
  • PhD, Indiana University - Indianapolis (2010)
Undergraduate School
  • BS, Indiana University System (IN) (2004)
Internship
  • East Tennessee State University Program (2013)
Residency
  • University of Colorado (University Hospital) Program, Chief Resident, Neurology (2016)
Fellowships
  • University of Colorado (University Hospital) Program, Neuromuscular Medicine (2017)
Department
Neurology

Publications

  • Poe, J., Lozowska, D., & Dixon, S. (2019). Statin Autoimmune Necrotizing Myopathy Diagnosed After a Motor Vehicle Accident. Marshall Journal of Medicine, 5(1), 6.
  • Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. (in preparation). Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective. Muscle & Nerve.
  • Dixon, S.E., Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Arnold, WD. (in preparation). Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve.
  • Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. (in preparation). Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life. Journal of Orphanet.
  • Dixon SE and Quan D. “Electromyography and nerve conduction studies.” In: West SG, Kolfenbach JR, eds., Rheumatology Secrets, 4th edition. Philadelphia: Elsevier Mosby, 2019, pp. 85-88.
  • Wilson Z and Dixon SE, “Appropriate Pain Management Following Open Muscle.” Carrell-Krusen Neuromuscular Symposium, Dallas, TX (Feb 2019, Poster presentation).
  • Kang X, Fridman V, and Dixon SE, “Two Interesting Cases of Fiber Type Disproportion”. Carrell-Krusen Neuromuscular Symposium, Dallas, TX (Feb 2020, submitted).
  • Chen E, Monnette A, Bazzano A, Hong D, Dixon SE, Arnold WD, Shi, L, “Preference of treatment characteristics among patients with spinal muscular atrophy (SMA): A discrete choice experiment”. AAN Annual Meeting, Toronto, Canada (April-May 2020, submitted).
  • Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective.
  • Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, Dixon, S.E, S., Arnold, WD. Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers.
  • Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life.
  • Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S., Arnold, WD., Shi, L., Treatment Preference among Patients with Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment.
  • Chen E, Dixon S, Naik R, Noone JM, Buchenberger JD, Whitmire SM, Mills R, Arnold W. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle Nerve. 2021 Mar;63(3):311-319. PubMed PMID: 33184859
  • Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021 Jan 20;16(1):36. PubMed PMID: 33472673
  • Chen E., Dixon, S.E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Mills, R., Arnold, W. (2021). Early experiences in the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve, 63(13), 311-319.
  • Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S.E., Arnold, WD., Shi, L. (2021). Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases, 20;16(1):36
  • Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 Jan;20(1):49-59.
  • Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF, CHAMPION MG Study Group. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022; 1 (5)
  • Lafreniere M, Dixon SE, “Thoughts and Perceptions of Risdiplam from Adults with SMA.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
  • Petluru M, Dixon SE, “Worsening Upper Extremity Weakness Seen as a Side Effect of Risdiplam in Adults with Spinal Muscular Atrophy.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
  • Phillips J, Dixon S, Koehler T, Kluger B. Advance Care Planning Among Patients With Amyotrophic Lateral Sclerosis: Patient Perspectives on Goals of Care Conversations. Am J Hosp Palliat Care. 2023 Apr 27;:10499091231172901. [Epub ahead of print] PubMed PMID: 37128837
  • Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023 Aug;270(8):3862-3875. PubMed PMID: 37103755
  • Lafreniere M, Dixon SE, Kammeyer R, Declusin A, “Cognitive changes, weakness, and myoclonus in a 78-year old man: a case presentation.” Carrell-Krusen Neuromuscular Symposium, Dallas, TX (February 2023, poster presentation).
  • Dixon S, Kang X, Quan, D. Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis. Therapeutics and Clinical Risk Management 2023:19 973–981.
  • Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews KD, Weihl CC, Wicklund M, Hung M, Statland J, Johnson NE. Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study. BMC Neurol. 2024 Mar 15;24(1):96. PubMed PMID: 38491364
  • Phillips J, Dixon S, Koehler T, Kluger B. Advance Care Planning Among Patients With Amyotrophic Lateral Sclerosis: Patient Perspectives on Goals of Care Conversations. Am J Hosp Palliat Care. 2024 Mar;41(3):295-301. PubMed PMID: 37128837

Practice Locations

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Rocky Mountain Regional Veterans Administration Medical Center
1700 Wheeling St
Aurora, CO 80045
303-399-8020

Hospital Affiliation
  • University of Colorado Hospital
  • Veterans Affairs Medical Center

Specialty Information

Specialties
  • Neurology, Board Certification
  • Neuromuscular Medicine
Conditions & Treatments
  • Brain and Nervous System - Neuromuscular Diseases
  • Brain and Nervous System
Clinical Interests
Neuromuscular disorders including: muscular dystrophies, acquired muscle diseases such as dermatomyositis and polymyositis, acquired peripheral nervous system disorders such as Guillain-Barre syndrome and CIDP.